Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Welcome and Introduction to Vi3C

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

May

Today In Oncology

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

Smoking Cessation Regimens: Does Dose of Therapy Matter?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos